EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A novel gain-of-function phosphorylation site modulates PTPN22 inhibition of TCR signaling

Chuling Zhuang, Shen Yang, Carlos G Gonzalez, Richard I Ainsworth, Sheng Li, Masumi Takayama Kobayashi, Igor Wierzbicki, Leigh-Ana M Rossitto, Yutao Wen, Wolfgang Peti, Stephanie M Stanford, David J Gonzalez und 3 weitere

Journal of Biological Chemistry · 2024

DOI: 10.1016/j.jbc.2024.107393 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2024. Verfasst von Chuling Zhuang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, California, USA. Hauptthemen laut MEDLINE: Receptors, Antigen, T-Cell, Protein Tyrosine Phosphatase, Non-Receptor Type 22, Signal Transduction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, University of California, San Diego, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) is encoded by a major autoimmunity gene and is a known inhibitor of T cell receptor (TCR) signaling and drug target for cancer immunotherapy. However, little is known about PTPN22 posttranslational regulation. Here, we characterize a phosphorylation site at Ser325 situated C terminal to the catalytic domain of PTPN22 and its roles in altering protein function. In human T cells, Ser325 is phosphorylated by glycogen synthase kinase-3 (GSK3) following TCR stimulation, which promotes its TCR-inhibitory activity. Signaling through the major TCR-dependent pathway under PTPN22 control was enhanced by CRISPR/Cas9-mediated suppression of Ser325 phosphorylation and inhibited by mimicking it via glutamic acid substitution. Global phospho-mass spectrometry showed Ser325 phosphorylation state alters downstream transcriptional activity through enrichment of Swi3p, Rsc8p, and Moira domain binding proteins, and next-generation sequencing revealed it differentially regulates the expression of chemokines and T cell activation pathways. Moreover, in vitro kinetic data suggest the modulation of activity depends on a cellular context. Finally, we begin to address the structural and mechanistic basis for the influence of Ser325 phosphorylation on the protein's properties by deuterium exchange mass spectrometry and NMR spectroscopy. In conclusion, this study explores the function of a novel phosphorylation site of PTPN22 that is involved in complex regulation of TCR signaling and provides details that might inform the future development of allosteric modulators of PTPN22.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Antigen, T-CellProtein Tyrosine Phosphatase, Non-Receptor Type 22Signal TransductionHumansPhosphorylationGain of Function MutationT-LymphocytesJurkat CellsHEK293 Cells

Stichwörter der Autor:innen

PTPN22T cell receptorallosteric regulationautoimmunitycatalysisintrinsically disordered regionphosphoproteomicsphosphorylationtranscriptomicstyrosine phosphatase

Substanzen

Receptors, Antigen, T-CellProtein Tyrosine Phosphatase, Non-Receptor Type 22PTPN22 protein, human

Autor:innen und Institutionen

  • Department of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, California, USA.
  • Department of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, California, USA; Department of Medicine, Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los An…
  • Department of Pharmacology, University of California, San Diego, California, USA; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, California, USA.
  • Department of Medicine, Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Department of Medicine, University of California, San Diego, California, USA.
  • Department of Molecular Biology and Biophysics, University of Connecticut Health, Farmington, Connecticut, USA.

Förderung

  • NIGMS NIH HHS
  • University of California, San Diego
  • National Institute of General Medical Sciences

Zitieren

APA

Zhuang, C., Yang, S., Gonzalez, C. G., Ainsworth, R. I., Li, S., Kobayashi, M. T., Wierzbicki, I., Rossitto, L. M., Wen, Y., Peti, W., Stanford, S. M., Gonzalez, D. J., Murali, R., Santelli, E., & Bottini, N. (2024). A novel gain-of-function phosphorylation site modulates PTPN22 inhibition of TCR signaling. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2024.107393

Vancouver

Zhuang C, Yang S, Gonzalez CG, Ainsworth RI, Li S, Kobayashi MT, et al. A novel gain-of-function phosphorylation site modulates PTPN22 inhibition of TCR signaling. Journal of Biological Chemistry. 2024. doi:10.1016/j.jbc.2024.107393

BibTeX
@article{Zhuang2024,
  author = {Zhuang, Chuling and Yang, Shen and Gonzalez, Carlos G and Ainsworth, Richard I and Li, Sheng and Kobayashi, Masumi Takayama and Wierzbicki, Igor and Rossitto, Leigh-Ana M and Wen, Yutao and Peti, Wolfgang and Stanford, Stephanie M and Gonzalez, David J and Murali, Ramachandran and Santelli, Eugenio and Bottini, Nunzio},
  title = {A novel gain-of-function phosphorylation site modulates PTPN22 inhibition of TCR signaling},
  journal = {Journal of Biological Chemistry},
  year = {2024},
  doi = {10.1016/j.jbc.2024.107393}
}
Kostenlos starten →